Page 11 - Gene Kinney News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesRichard hargreavesJennifer zibudaDevelopment collaborationInvestor relations communicationsCompany on twitter prothenacorpExchange commissionGlobal neuroscience researchBristol myers squibbProthena corporationGene kinneyChief executive officerSenior vice presidentNeuroscience thematic researchProspectus supplementInvestor relations

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesRichard hargreavesJennifer zibudaBristol myers squibb opt inDevelopment collaborationFirst programInvestor relations communicationsCompany on twitter prothenacorpExchange commissionGlobal neuroscience researchBristol myers squibbProthena corporationProthena announces bristol myers squibb opt inGene kinneyChief executive officerSenior vice president

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

VITAL study 9-month results expected to be presented at a medical conference in 2021 Prasinezumab Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference PRX004 PRX005 IND expected by 3Q 2021 $80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021 PRX012, a potential treatment for Alzheimer’s disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aβ IND expected by 1Q 2022 Upcoming Investor Conferences Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences: BofA Securities 2021 Virtual Health Care Conference, May 13, 2021, at 8:45 AM ET

United statesHideki garrenJennifer zibudaRoche ltdInvestor relations communicationsDrug administrationInternational conference on alzheimerCompany on twitter prothenacorpExchange commissionRoche genentech incAmerican academy of neurologyBristol myers squibbVirtual healthcare conferenceProthena corporationProthena reports first quarterProvides updated financial guidance

Prothena Corporation plc: Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

Prothena Corporation plc: Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update VITAL study 9-month results expected to be presented at a medical conference in 2021 Prasinezumab Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference PRX004 PRX005 IND expected by 3Q 2021 $80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021 PRX012, a potential treatment for Alzheimer s disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aß IND expected by 1Q 2022 Upcoming Investor Conferences Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences:

United statesHideki garrenJennifer zibudaRoche ltdInvestor relations communicationsDrug administrationInternational conference on alzheimerCompany on twitter prothenacorpExchange commissionRoche genentech incAmerican academy of neurologyBristol myers squibbVirtual healthcare conferenceProthena corporationMayo stageChief medical officer

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Stanford universityUnited statesCalifornia institute of technologyLos angelesEllen roseJennifer zibudaHideki garrenRoche neuroimmunologyNovartis pharmaRoche ltdUniversity of californiaHead of communicationsInvestor relations communicationsRoche genentech incBayhill therapeutics incProthena corporation